Analysed KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) News Sources
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
04-05-2026
yahoo.com
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
03-06-2026
yahoo.com
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
08-06-2026
fool.com
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
22-06-2026
yahoo.com
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
27-07-2026
yahoo.com
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
11-08-2026
yahoo.com
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
02-09-2026
biopharmadive.com
What is the current price of KYVERNA THERAPEUTICS INC (KYTX:NASDAQ)?
The current price of KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) is $8.24.
KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) since the previous trading day is $-0.11.
KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) since the previous trading day is -1.3174%.
What is the most recent average sentiment score for KYVERNA THERAPEUTICS INC (KYTX:NASDAQ)?
The most recent average sentiment score for KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for KYVERNA THERAPEUTICS INC (KYTX:NASDAQ)?
The most recent sentiment for KYVERNA THERAPEUTICS INC (KYTX:NASDAQ) is .
SEC-8K** Filing Available For KYVERNA THERAPEUTICS INC (KYTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.